KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) EBIT (2017 - 2026)

Cardlytics filings provide 10 years of EBIT readings, the most recent being -$8.3 million for Q1 2026.

  • Quarterly EBIT rose 25.56% to -$8.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$96.0 million through Mar 2026, up 47.76% year-over-year, with the annual reading at -$101.8 million for FY2025, 47.92% up from the prior year.
  • EBIT hit -$8.3 million in Q1 2026 for Cardlytics, down from -$6.1 million in the prior quarter.
  • Across five years, EBIT topped out at $35.7 million in Q1 2022 and bottomed at -$382.6 million in Q4 2022.
  • Average EBIT over 5 years is -$52.7 million, with a median of -$15.8 million recorded in 2024.
  • Peak annual rise in EBIT hit 260.84% in 2022, while the deepest fall reached 2231.86% in 2022.
  • Cardlytics' EBIT stood at -$382.6 million in 2022, then surged by 73.1% to -$102.9 million in 2023, then skyrocketed by 91.92% to -$8.3 million in 2024, then increased by 26.69% to -$6.1 million in 2025, then crashed by 35.75% to -$8.3 million in 2026.
  • Per Business Quant, the three most recent readings for CDLX's EBIT are -$8.3 million (Q1 2026), -$6.1 million (Q4 2025), and -$68.9 million (Q3 2025).